Sep 20, 2019
Harmony Biosciences Announces Recipients of 2019 Patients at the Heart Grant in Recognition of World Narcolepsy Day
Mar 20, 2019
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Oct 09, 2018
New Survey Identifies Need For Increased Education About And New Treatment Options For Narcolepsy
Sep 05, 2018
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming International Narcolepsy Symposium
Mar 12, 2018
Cost of Sleepiness Too Pricey to Ignore
Mar 02, 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Dec 21, 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Aug 03, 2017
Panasonic Develops Drowsiness-Control Technology by Detecting and Predicting Driver's Level of Drowsiness
Jun 06, 2017
Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea
Jun 06, 2017
Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy
Jun 06, 2017
The Global Sleep Wake Disorders Market is Expected to Grow With the CAGR of 16.8% (Approx.) During the Forecast Period 2016-2023: Occams Business Research & Consulting